Tempus AI (Nasdaq: TEM), an AI-based precision medicine company, will take the stage to directly explain its business strategy to global healthcare investors.

■ Conference to Be Held in New York on September 15; CEO Lefkofsky to Join Fireside Chat

Tempus AI announced that its founder and CEO, Eric Lefkofsky, will attend the Morgan Stanley 24th Annual Global Healthcare Conference, to be held in New York on September 15. CEO Lefkofsky will participate in a fireside chat at 8:30 a.m. (U.S. Eastern Time) that day, and the discussion will also be available via a live audio webcast online.

The event is drawing attention as an opportunity for Tempus AI to explain the direction of its precision medicine business, which combines AI and medical data, to global institutional investors.

■ Business Model Based on Multimodal Medical Data

Tempus AI provides AI-based precision medicine solutions to clinicians based on large-scale multimodal medical data and the software platform built to utilize it. A core part of its business is supporting personalized treatment decisions by analyzing patient-specific medical data.

Its business scope is not limited to patient care. Tempus AI has built a business model that leverages its accumulated medical data to support the discovery and development of therapeutics as well as their application in real clinical settings. In particular, the company's key direction is enabling clinicians to use the treatment histories and accumulated data of past patients when treating new patients — a structure in which the scope of AI and analytics tools expands as data grows.

■ Data Monetization Capability Key to Growth

In the AI industry, healthcare is regarded as a field where competitiveness is determined by securing large-scale data and the ability to apply it in actual clinical settings. How well Tempus AI can commercialize its self-built multimodal data assets in real clinical practice and new drug development processes is expected to be a key factor in judging its future growth potential.

However, this announcement concerns only the conference participation schedule; no new contracts, earnings guidance, or new product launches were disclosed. Markets are expected to watch whether CEO Lefkofsky's fireside chat on September 15 will present additional details on the growth strategy of its AI medical platform, the data business, and expanded collaborations in the pharmaceutical and biotech sectors.

[※ This article was written for the purpose of providing information on the stock market and companies, and does not recommend the purchase or sale of specific stocks or guarantee investment returns. A company's business plans and growth outlook may change depending on market conditions and management circumstances. Investment decisions and the resulting responsibility rest with the investor, so please fully review corporate disclosures and related information before investing. This article was written with AI assistance.]